

information. Therefore, a freedom of information summary is not required.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

#### List of Subjects in 21 CFR Part 520

Animal drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

#### PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: 21 U.S.C. 360b.

■ 2. In 520.2215, revise paragraph (c)(3) to read as follows:

#### § 520.2215 Sulfadiazine/pyrimethamine suspension.

\* \* \* \* \*

(c) \* \* \*

(3) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dated: September 5, 2008.

William T. Flynn,

Acting Director, Center for Veterinary Medicine.

[FR Doc. E8–21625 Filed 9–16–08; 8:45 am]

BILLING CODE 4160–01–S

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

#### 21 CFR Part 803

[Docket No. FDA–2008–N–0310]

#### Medical Devices; Medical Device Reporting; Baseline Reports; Confirmation of Effective Date

AGENCY: Food and Drug Administration, HHS.

ACTION: Direct final rule; confirmation of effective date.

**SUMMARY:** The Food and Drug Administration (FDA) is confirming the effective date of October 27, 2008, for the final rule that appeared in the **Federal Register** of June 13, 2008 (73 FR 33692). The direct final rule amends the Medical Device Reporting regulation by removing the requirement for baseline reports. This document confirms the effective date of the direct final rule.

**DATES:** Effective date confirmed: October 27, 2008.

**FOR FURTHER INFORMATION CONTACT:** Howard A. Press, Center for Devices and Radiological Health (HFZ–531), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 240–276–3457.

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of June 13, 2008 (73 FR 33692), FDA solicited comments concerning the direct final rule for a 75-day period ending August 27, 2008. FDA stated that the effective date of the direct final rule would be on October 27, 2008, 60 days after the end of the comment period, unless any significant adverse comment was submitted to FDA during the comment period. FDA did not receive any significant adverse comments.

**Authority:** Therefore, under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, and under authority delegated to the Commissioner of Food and Drugs, the amendments issued thereby become effective on October 27, 2008.

Dated: September 11, 2008.

Jeffrey Shuren,

Associate Commissioner for Policy and Planning.

[FR Doc. E8–21756 Filed 9–16–08; 8:45 am]

BILLING CODE 4160–01–S

#### MILLENNIUM CHALLENGE CORPORATION

#### 22 CFR Part 1304

#### Regulations Implementing the Freedom of Information Act

AGENCY: Millennium Challenge Corporation.

ACTION: Final rule.

**SUMMARY:** The Millennium Challenge Corporation is issuing a final rule to update its Freedom of Information Act regulations. The purpose of this final rule is to outline the procedures by which the Millennium Challenge Corporation proposes to implement the relevant provisions of the Freedom of Information Act as required under that statute. This document will assist interested parties in obtaining access to

Millennium Challenge Corporation public records.

**DATES:** This final rule is effective on September 17, 2008.

**ADDRESSES:** Send comments to John Mantini, FOIA Officer, Office of the General Counsel, Millennium Challenge Corporation, 875 Fifteenth Street, NW., Washington, DC 20005–2221.

**FOR FURTHER INFORMATION CONTACT:** John Mantini, FOIA Officer, 202–521–3863.

**SUPPLEMENTARY INFORMATION:** The Millennium Challenge Act (MCA) of 2003 established a new federal agency called the Millennium Challenge Corporation. Congress enacted the Freedom of Information Act (FOIA) in 1966 and last modified it with the Electronic Freedom of Information Act amendments of 1996. On August 28, 2007, the Millennium Challenge Corporation published a proposed rule in the **Federal Register**, 72 FR 49238, Aug. 28, 2007 to outline its procedures to implement the FOIA regulations and requested public comments. The Millennium Challenge Corporation received no comments during the 60-day comment period. The Millennium Challenge Corporation's final regulations are identical to those in the proposed rule.

This final rule addresses electronically available documents, procedures for making requests, agency handling of requests, records not disclosed, changes in fees, and public reading rooms as well as other related provisions.

#### List of Subjects in 22 Part 1304

Freedom of Information Act Procedures.

■ For the reasons set forth in the preamble, the Millennium Challenge Corporation adds 22 CFR part 1304 as follows:

#### PART 1304—FREEDOM OF INFORMATION ACT PROCEDURES

Sec.

1304.1 General Provisions.

1304.2 Definitions.

1304.3 Records available to the public.

1304.4 Requests for records.

1304.5 Responsibility for responding to requests.

1304.6 Records not disclosed.

1304.7 Confidential commercial information.

1304.8 Appeals.

1304.9 Fees.

Authority: 5 U.S.C. 552, as amended.

#### § 1304.1 General Provisions.

This part contains the regulations the Millennium Challenge Corporation (MCC) follows in implementing the